The Impact of PSMA PET/CT on Modern Prostate Cancer Management and Decision Making—The Urological Perspective

Hoffman, Azik; Amiel, Gilad E.

doi:10.3390/cancers15133402

Cited by 10 publications

(2 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, 18F-FDG, 68Ga-peptides and PSMA radioligands seem to be the most used tracers for PET/ceCT. This is line with recent literature, suggesting possible role of PET/ceCT in NET and prostate cancer management (1,8,9).…”

Section: Discussionsupporting

confidence: 93%

“…In the 21st century, Positron Emission Tomography (PET) imaging with 18F-Fluorodeoxyglucose (18F-FDG) and other radiopharmaceuticals emerged as a precious diagnostic tool in several clinical settings, including oncology, neurology, medicine and surgery, thanks to the added functional information in diagnosis, staging, restaging and treatment evaluation of an increasing number of diseases ( 1 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Contrast enhanced CT on PET/CT imaging in clinical routine: an international survey

Annunziata,

Testart,

Auf der Springe

et al. 2023

Front. Med.

View full text Add to dashboard Cite

AimTo perform an international survey about PET/CT imaging with contrast enhanced CT (PET/ceCT) in clinical routine worldwide.MethodsA questionnaire of ten questions was prepared for health professionals, addressing the following issues: (1) general demographic, hospital, and department information; (2) use and diffusion of PET/ceCT worldwide; (3) factors influencing the use of PET/ceCT. An invitation to the survey was sent to the corresponding authors of NM scientific articles indexed in SCOPUS in 2022 and dedicated to PET/CT imaging. Data were analysed per individual responder.Results191 individual responders worldwide participated in this survey. Most of the responders are using PET/ceCT in their center (74%). Interestingly, the relative use of PET/ceCT over the total PET/CT scans has an anti-Gaussian distribution (<20% ceCT and > 80% ceCT were most represented). Most of responders are using PET/ceCT in oncological settings (62%) and irrespectively from radiopharmaceuticals (62%). In most cases, PET/ceCT scans are reported by NM physicians alone or together by NM physicians and radiologists with an integrated report (31%).ConclusionPET/ceCT imaging is largely used worldwide. Local factors can affect the choice of PET/ceCT in respect to conventional PET/CT imaging. Further cost–benefit analysis could be useful to consider other possible influencing variables, such as technologies, dosimetry, department organization and economics.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Introductionmentioning

confidence: 99%

Contrast enhanced CT on PET/CT imaging in clinical routine: an international survey

Annunziata,

Testart,

Auf der Springe

et al. 2023

Front. Med.

View full text Add to dashboard Cite

show abstract

Standardized template for clinical reporting of PSMA PET/CT scans

Esfahani,

Morris,

Sartor

et al. 2024

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Purpose Accurate diagnosis and staging of prostate cancer are crucial to improving patient care. Prostate-specific membrane antigen (PSMA)-targeted positron emission tomography with computed tomography (PET/CT) imaging has demonstrated superiority for initial staging and restaging in patients with prostate cancer. Referring physicians and PET/CT readers must agree on a consistent communication method and application of information derived from this imaging modality. While several guidelines have been published, a single PSMA PET/CT reporting template has yet to be widely adopted. Based on the consensus from community and academic physicians, we developed a standardized PSMA PET/CT reporting template for radiologists and nuclear medicine physicians to report and relay key imaging findings to referring physicians. The aim was to improve the quality, clarity, and utility of imaging results reporting to facilitate patient management decisions. Methods Based on community and expert consensus, we developed a standardized PSMA PET/CT reporting template to deliver key imaging findings to referring clinicians. Results Core category components proposed include a summary of any prior treatment history; presence, location, and degree of PSMA radiopharmaceutical uptake in primary and/or metastatic tumor(s), lesions with no uptake, and incidentally found lesions with positive uptake on PET/CT. Conclusions This article provides recommendations on best practices for standardized reporting of PSMA PET/CT imaging. The generated reporting template is a proposed supplement designed to educate and improve data communication between imaging experts and referring physicians.

show abstract

Targeting glutamate carboxypeptidase II in IBD

Peters

2024

Advances in Pharmacology

View full text Add to dashboard Cite

The Impact of PSMA PET/CT on Modern Prostate Cancer Management and Decision Making—The Urological Perspective

Cited by 10 publications

References 53 publications

Contrast enhanced CT on PET/CT imaging in clinical routine: an international survey

Contrast enhanced CT on PET/CT imaging in clinical routine: an international survey

Standardized template for clinical reporting of PSMA PET/CT scans

Targeting glutamate carboxypeptidase II in IBD

Contact Info

Product

Resources

About